CurrentUnitedHealthcarePolicy 2025 1473-1

Hympavzi (marstacimab-hnca) prior authorization policy

Defines UnitedHealthcare prior authorization and reauthorization criteria for Hympavzi (marstacimab-hnca) for routine prophylaxis to prevent bleeding in patients ≥12 years with hemophilia A or B without inhibitors, authorization durations, and use of automated approval processes.

Policy Summary

PayerUnitedHealthcare

PolicyHympavzi (marstacimab-hnca) prior authorization policy

Policy CodePolicy 2025 1473-1

Change TypeNew program (Prior Authorization/Notification)

Effective DateJul 1, 2025

Next Review Date

Key ActionPrior authorization/notification is required for Hympavzi; initial approvals issued for 12 months when all initial criteria met.

SourceLink

POLICY UPDATE CHANGES

New program for Hympavzi added with P&T approval March 2025 and effective date 7/1/2025.

2Covered Indications (hemophilia A and B)

12 monthsApproval duration (initial and reauthorization)

>=12Minimum patient age

Coverage Summary

Defines UnitedHealthcare prior authorization and reauthorization criteria for Hympavzi (marstacimab-hnca) for routine prophylaxis to prevent bleeding in patients ≥12 years with hemophilia A or B without inhibitors. Policy number: 2025 1473-1. Effective date: 2025-07-01. Coverage stance: covered_with_criteria for the indication of routine prophylaxis to prevent or reduce bleeding episodes in patients ≥12 years with hemophilia A or B without inhibitors.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy Criteria

Initial Authorization - Hemophilia A

Hympavzi will be approved based on ALL of the following criteria

Diagnosis of hemophilia A
Age: Patient is 12 years of age or older>= 12 years
Indication: Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)
See 'Routine prophylaxis' definition.
Inhibitor status: Patient does not have a history of inhibitors to factor VIII

Authorization duration: Authorization of therapy will be issued for 12 months12 months

Initial Authorization - Hemophilia B

Hympavzi will be approved based on ALL of the following criteria

Diagnosis of hemophilia B
Age: Patient is 12 years of age or older>= 12 years
Indication: Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)
See 'Routine prophylaxis' definition.
Inhibitor status: Patient does not have a history of inhibitors to factor IX

Continuation / Reauthorization Criteria

Reauthorization - Hemophilia A

Reauthorization criteria

Reauthorization - Hemophilia A: Documentation of positive clinical response to Hympavzi therapy

Reauthorization duration: 12 months.

Reauthorization - Hemophilia B

Reauthorization criteria

Reauthorization - Hemophilia B: Documentation of positive clinical response to Hympavzi therapy

Reauthorization duration: 12 months.

Provider Actions

Prior Authorization

Prior authorization required

Prior authorization/notification is required for Hympavzi; initial approvals are issued for 12 months when all initial criteria are met.

Initial approval duration = 12 months

Documentation Required

Reauthorization documentation

For reauthorization, the provider must document a positive clinical response to Hympavzi therapy; reauthorizations are issued for 12 months.

Billing Rule

Automated approval allowance

UnitedHealthcare may approve initial and reauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic; use of automated approval and re-approval processes varies by program.

Denial Risk

Inhibitor exclusion

Claims may be denied if the patient has a history of inhibitors to factor VIII (hemophilia A) or factor IX (hemophilia B).

Background

Hympavzi (marstacimab-hnca) is a TFPI antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years and older with hemophilia A (congenital factor VIII deficiency) or hemophilia B (congenital factor IX deficiency) without inhibitors. Policy number: 2025 1473-1. Effective date: 2025-07-01. Last review date: 2025-03-01.

Routine prophylaxis: Prescribed for the prevention of bleeding episodes (as stated in policy).